# Evolent Health, Inc.: financial statements, quarterly

EVH · NYSE · CIK 1628908 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/evh.md) · [Financials](/companies/evh/financials.md) · [Filings](/companies/evh/filings.md) · [Insiders](/companies/evh/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/evh/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [511](/filings/0001628908-25-000020.md) | [556](/filings/0001628908-25-000020.md) | [640](/filings/0001628908-26-000015.md) | [647](/filings/0001628908-26-000015.md) | [621](/filings/0001628908-26-000015.md) | [647](/filings/0001628908-26-000015.md) | [484](/filings/0001628908-26-000033.md) | [444](/filings/0001628908-26-000086.md) | [480](/filings/0001628908-26-000015.md) | [469](/filings/0001628908-26-000015.md) | [496](/filings/0001628908-26-000033.md) | [653](/filings/0001628908-26-000086.md) |
| Cost of revenue | $m | [387](/filings/0001628908-24-000114.md) | [454 d](/filings/0001628908-26-000015.md) | [536](/filings/0001628908-25-000066.md) | [540](/filings/0001628908-25-000116.md) | [541](/filings/0001628908-25-000133.md) | [571 d](/filings/0001628908-26-000015.md) | [381](/filings/0001628908-26-000033.md) | [344](/filings/0001628908-26-000086.md) | [380](/filings/0001628908-25-000133.md) | [371 d](/filings/0001628908-26-000015.md) | [412](/filings/0001628908-26-000033.md) | [572](/filings/0001628908-26-000086.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [96.6](/filings/0001628908-24-000114.md) | [81.4 d](/filings/0001628908-26-000015.md) | [79.1](/filings/0001628908-25-000066.md) | [69.2](/filings/0001628908-25-000116.md) | [67.1](/filings/0001628908-25-000133.md) | [47.7 d](/filings/0001628908-26-000015.md) | [78.4](/filings/0001628908-26-000033.md) | [75.2](/filings/0001628908-26-000086.md) | [77.6](/filings/0001628908-25-000133.md) | [72.7 d](/filings/0001628908-26-000015.md) | [72.8](/filings/0001628908-26-000033.md) | [68.8](/filings/0001628908-26-000086.md) |
| Operating income | $m | [(17.9)](/filings/0001628908-24-000114.md) | [(21.4) d](/filings/0001628908-26-000015.md) | [(13.4)](/filings/0001628908-25-000066.md) | [7.8](/filings/0001628908-25-000116.md) | [(16.3)](/filings/0001628908-25-000133.md) | [(18.6) d](/filings/0001628908-26-000015.md) | [(1.6)](/filings/0001628908-26-000033.md) | [(1.2)](/filings/0001628908-26-000086.md) | [0.9](/filings/0001628908-25-000133.md) | [(408) d](/filings/0001628908-26-000015.md) | [(10.6)](/filings/0001628908-26-000033.md) | [(9.6)](/filings/0001628908-26-000086.md) |
| Interest expense | $m | [14.6](/filings/0001628908-23-000165.md) | [12.2 d](/filings/0001628908-24-000017.md) | [6.0](/filings/0001628908-24-000053.md) | [6.0](/filings/0001628908-25-000116.md) | [6.0](/filings/0001628908-25-000133.md) | [6.7 d](/filings/0001628908-26-000015.md) | [10.4](/filings/0001628908-26-000033.md) | [11.6](/filings/0001628908-26-000086.md) | [16.5](/filings/0001628908-25-000133.md) | [19.0 d](/filings/0001628908-26-000015.md) | [16.9](/filings/0001628908-26-000033.md) | [16.9](/filings/0001628908-26-000086.md) |
| Income tax | $m | [(5.6)](/filings/0001628908-24-000114.md) | [(14.7) d](/filings/0001628908-26-000015.md) | [0.6](/filings/0001628908-25-000066.md) | [(0.2)](/filings/0001628908-25-000116.md) | [(0.6)](/filings/0001628908-25-000133.md) | [(1.1) d](/filings/0001628908-26-000015.md) | [1.5](/filings/0001628908-26-000033.md) | [(0.8)](/filings/0001628908-26-000086.md) | [0.9](/filings/0001628908-25-000133.md) | [(1.7) d](/filings/0001628908-26-000015.md) | [0.9](/filings/0001628908-26-000033.md) | [2.7](/filings/0001628908-26-000086.md) |
| Net income | $m | [(25.3)](/filings/0001628908-25-000020.md) | [(33.4)](/filings/0001628908-25-000020.md) | [(17.3)](/filings/0001628908-26-000015.md) | [1.6](/filings/0001628908-26-000015.md) | [(23.1)](/filings/0001628908-26-000015.md) | [(22.8)](/filings/0001628908-26-000015.md) | [(64.6)](/filings/0001628908-26-000033.md) | [(19.9)](/filings/0001628908-26-000086.md) | [(20.9)](/filings/0001628908-26-000015.md) | [(429)](/filings/0001628908-26-000015.md) | [(26.6)](/filings/0001628908-26-000033.md) | [(28.4)](/filings/0001628908-26-000086.md) |
| Diluted EPS | $ per share | [(0.30)](/filings/0001628908-25-000020.md) | [(0.36)](/filings/0001628908-25-000020.md) | [(0.22)](/filings/0001628908-26-000015.md) | [(0.06)](/filings/0001628908-26-000015.md) | [(0.27)](/filings/0001628908-26-000015.md) | [(0.27)](/filings/0001628908-26-000015.md) | [(0.63)](/filings/0001628908-26-000033.md) | [(0.44)](/filings/0001628908-26-000086.md) | [(0.24)](/filings/0001628908-26-000015.md) | [(3.84)](/filings/0001628908-26-000015.md) | [(0.24)](/filings/0001628908-26-000033.md) | [(0.25)](/filings/0001628908-26-000086.md) |
| Basic EPS | $ per share | [(0.30)](/filings/0001628908-25-000020.md) | [(0.36)](/filings/0001628908-25-000020.md) | [(0.22)](/filings/0001628908-26-000015.md) | [(0.06)](/filings/0001628908-26-000015.md) | [(0.27)](/filings/0001628908-26-000015.md) | [(0.27)](/filings/0001628908-26-000015.md) | [(0.63)](/filings/0001628908-26-000033.md) | [(0.44)](/filings/0001628908-26-000086.md) | [(0.24)](/filings/0001628908-26-000015.md) | [(3.84)](/filings/0001628908-26-000015.md) | [(0.24)](/filings/0001628908-26-000033.md) | [(0.25)](/filings/0001628908-26-000086.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [185](/filings/0001628908-24-000114.md) | [193](/filings/0001628908-25-000020.md) | [165](/filings/0001628908-25-000066.md) | [101](/filings/0001628908-25-000116.md) | [96.6](/filings/0001628908-25-000133.md) | [104](/filings/0001628908-26-000015.md) | [247](/filings/0001628908-26-000033.md) | [151](/filings/0001628908-26-000086.md) | [117](/filings/0001628908-25-000133.md) | [152](/filings/0001628908-26-000086.md) | [142](/filings/0001628908-26-000033.md) | [116](/filings/0001628908-26-000086.md) |
| Current assets | $m | [639](/filings/0001628908-23-000165.md) | [684](/filings/0001628908-25-000020.md) | [669](/filings/0001628908-24-000053.md) | [521](/filings/0001628908-24-000090.md) | [544](/filings/0001628908-24-000114.md) | [607](/filings/0001628908-26-000015.md) | [728](/filings/0001628908-25-000066.md) | [562](/filings/0001628908-25-000116.md) | [570](/filings/0001628908-25-000133.md) | [506](/filings/0001628908-26-000086.md) | [502](/filings/0001628908-26-000033.md) | [611](/filings/0001628908-26-000086.md) |
| Total assets | $m | [2,670](/filings/0001628908-23-000165.md) | [2,680](/filings/0001628908-25-000020.md) | [2,644](/filings/0001628908-24-000053.md) | [2,475](/filings/0001628908-24-000090.md) | [2,502](/filings/0001628908-24-000114.md) | [2,544](/filings/0001628908-26-000015.md) | [2,653](/filings/0001628908-25-000066.md) | [2,462](/filings/0001628908-25-000116.md) | [2,453](/filings/0001628908-25-000133.md) | [1,899](/filings/0001628908-26-000086.md) | [1,879](/filings/0001628908-26-000033.md) | [1,972](/filings/0001628908-26-000086.md) |
| Current liabilities | $m | [615](/filings/0001628908-23-000165.md) | [674](/filings/0001628908-25-000020.md) | [659](/filings/0001628908-24-000053.md) | [483](/filings/0001628908-24-000090.md) | [524](/filings/0001628908-24-000114.md) | [716](/filings/0001628908-26-000015.md) | [739](/filings/0001628908-25-000066.md) | [558](/filings/0001628908-25-000116.md) | [430](/filings/0001628908-25-000133.md) | [385](/filings/0001628908-26-000086.md) | [381](/filings/0001628908-26-000033.md) | [493](/filings/0001628908-26-000086.md) |
| Total liabilities | $m | [1,398](/filings/0001628908-23-000165.md) | [1,434](/filings/0001628908-25-000020.md) | [1,414](/filings/0001628908-24-000053.md) | [1,237](/filings/0001628908-24-000090.md) | [1,276](/filings/0001628908-24-000114.md) | [1,353](/filings/0001628908-26-000015.md) | [1,525](/filings/0001628908-25-000066.md) | [1,337](/filings/0001628908-25-000116.md) | [1,611](/filings/0001628908-25-000133.md) | [1,484](/filings/0001628908-26-000086.md) | [1,482](/filings/0001628908-26-000033.md) | [1,589](/filings/0001628908-26-000086.md) |
| Long-term debt | $m | [600](/filings/0001628908-23-000165.md) | [597](/filings/0001628908-25-000020.md) | [598](/filings/0001628908-24-000053.md) | [599](/filings/0001628908-24-000090.md) | [600](/filings/0001628908-24-000114.md) | [491](/filings/0001628908-26-000015.md) | [648](/filings/0001628908-25-000066.md) | [648](/filings/0001628908-25-000116.md) | [1,055](/filings/0001628908-25-000133.md) | [971](/filings/0001628908-26-000086.md) | [973](/filings/0001628908-26-000033.md) | [966](/filings/0001628908-26-000086.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [1.0](/filings/0001628908-23-000165.md) | [0.0](/filings/0001628908-25-000020.md) | not reported | not reported | not reported | [171](/filings/0001628908-26-000015.md) | [172](/filings/0001628908-25-000066.md) | [172](/filings/0001628908-25-000116.md) | [5.1](/filings/0001628908-25-000133.md) | [0.0](/filings/0001628908-26-000015.md) | not reported | not reported |
| Shareholders' equity | $m | [1,096](/filings/0001628908-24-000114.md) | [1,068](/filings/0001628908-26-000015.md) | [1,048](/filings/0001628908-25-000116.md) | [1,054](/filings/0001628908-25-000133.md) | [1,039](/filings/0001628908-25-000133.md) | [1,001](/filings/0001628908-26-000086.md) | [936](/filings/0001628908-26-000086.md) | [896](/filings/0001628908-26-000086.md) | [842](/filings/0001628908-25-000133.md) | [415](/filings/0001628908-26-000086.md) | [396](/filings/0001628908-26-000086.md) | [383](/filings/0001628908-26-000086.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [60.5 d](/filings/0001628908-24-000114.md) | [89.4 d](/filings/0001628908-26-000015.md) | [4.9](/filings/0001628908-25-000066.md) | [21.4 d](/filings/0001628908-25-000116.md) | [18.7 d](/filings/0001628908-25-000133.md) | [(26.2) d](/filings/0001628908-26-000015.md) | [4.6](/filings/0001628908-26-000033.md) | [(30.3) d](/filings/0001628908-26-000086.md) | [15.8 d](/filings/0001628908-25-000133.md) | [48.8 d](/filings/0001628908-26-000015.md) | [(1.0)](/filings/0001628908-26-000033.md) | [(9.3) d](/filings/0001628908-26-000086.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001628908-26-000015.md) | not reported | not reported | not reported | [0.0 d](/filings/0001628908-26-000015.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [99.3](/filings/0001628908-23-000165.md) | [108](/filings/0001628908-24-000053.md) | [111](/filings/0001628908-24-000090.md) | [112](/filings/0001628908-24-000114.md) | [114](/filings/0001628908-25-000066.md) | [115](/filings/0001628908-25-000116.md) | [115](/filings/0001628908-25-000133.md) | [115](/filings/0001628908-26-000033.md) | [116](/filings/0001628908-26-000086.md) | [114](/filings/0001628908-25-000133.md) | [112](/filings/0001628908-26-000033.md) | [113](/filings/0001628908-26-000086.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 113,059,335 at 2026-08-01, from the cover of the [10-Q filed 2026-08-06](/filings/0001628908-26-000086.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.